Yong Liu

Title: Yong Liu - Innovator in Cancer Treatment

Introduction

Yong Liu is a prominent inventor based in Nanjing, China. He has made significant contributions to the field of cancer treatment through his innovative research and patents. His work focuses on developing binding moieties that target specific cancer markers, which can lead to more effective therapies.

Latest Patents

Yong Liu holds a patent for "Claudin18.2 binding moieties and uses thereof." This patent describes binding moieties, such as antibodies, that specifically bind to Claudin18.2. It also includes chimeric antigen receptors that incorporate these binding moieties. Furthermore, the patent outlines engineered immune cells, such as T cells, that contain anti-Claudin 18.2 chimeric antigen receptors. The methods disclosed in this patent aim to treat Claudin18.2-expressing tumors or cancers using these innovative binding moieties and engineered immune cells. Yong Liu has 1 patent to his name.

Career Highlights

Throughout his career, Yong Liu has worked with notable companies in the biotechnology sector, including Nanjing Genscript Biotech Co., Ltd. and Nanjing Legend Biotech Co., Ltd. His experience in these organizations has allowed him to advance his research and contribute to the development of cutting-edge cancer therapies.

Collaborations

Yong Liu has collaborated with esteemed colleagues in his field, including Liusong Yin and Tielin Zhou. These partnerships have fostered a collaborative environment that enhances innovation and research in cancer treatment.

Conclusion

Yong Liu's contributions to cancer treatment through his innovative patents and collaborations highlight his role as a leading inventor in the biotechnology field. His work continues to pave the way for advancements in targeted cancer therapies.